Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Top Page
Trevi Therapeutics
(NASDAQ:TRVI)
55Neutral
Positive Factors
Clinical Trials
The positive sample size re-estimation on CORAL and successfully completed abuse potential study are notable developments for TRVI.
Financial Stability
Trevi Therapeutics has a solid cash position of $107.6 million, providing financial stability until the second half of 2026.
Market Potential
The recent RCC data was transformational for TRVI not only for the significant expansion of Haduvio's market potential but also due to evidence of efficacy at the lowest dose evaluated.
Negative Factors
Financial Needs
Trevi does not have sufficient funds to complete the Phase 3 trial for IPF, indicating a need for additional financing in the future.
Market Perception
TRVI shares could see some weakness based on the 'likeability' of clinical doses of nalbuphine ER being above the 11-pt margin vs placebo.
Trevi Therapeutics (TRVI) vs. S&P 500 (SPY)
Market Cap
$618.77M
Dividend YieldN/A
Average Volume (3M)3.26M
Price to Earnings (P/E)―
Beta (1Y)-0.29
Revenue GrowthN/A
EPS Growth-60.26%
CountryUS
Employees26
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.47
Shares Outstanding96,682,230
10 Day Avg. Volume7,808,476
30 Day Avg. Volume3,256,925
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-16.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.85Price Target Upside194.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Trevi Therapeutics Business Overview & Revenue Model
Company DescriptionTrevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious neurological conditions. The company's lead product candidate, Haduvio, is being developed for the treatment of chronic pruritus (itch), and chronic cough in adults with idiopathic pulmonary fibrosis (IPF). Trevi Therapeutics operates within the biotechnology and pharmaceutical sectors, aiming to address unmet medical needs in these niche markets.
How the Company Makes MoneyTrevi Therapeutics primarily makes money through the development and potential commercialization of its lead product candidate, Haduvio. Revenue is anticipated to be generated from product sales once Haduvio receives regulatory approval and is launched in the market. The company may also explore partnerships and licensing agreements with larger pharmaceutical companies to enhance its distribution capabilities and reach. Additionally, Trevi might earn revenue from milestone payments or royalties associated with such partnerships. However, as a clinical-stage company, Trevi Therapeutics currently does not have any products on the market and relies on funding from investors to support its research and development activities.
Trevi Therapeutics Financial Statement Overview
Summary
Trevi Therapeutics faces significant financial challenges, with consistent losses and negative cash flows. While the low debt levels provide some buffer, the company must address its operational inefficiencies to achieve sustainable growth. The current financial trajectory indicates a need for strategic improvements to enhance profitability and liquidity.Income Statement
Trevi Therapeutics has struggled with profitability, as indicated by negative gross, EBIT, and net profit margins. The TTM (Trailing-Twelve-Months) shows some revenue generation, but the significant negative EBIT and net income margins highlight ongoing operational challenges.35
Negative
Balance Sheet
The company maintains a relatively low debt-to-equity ratio, which indicates conservative leverage. However, the declining stockholders' equity and limited asset growth signal potential financial constraints. The equity ratio remains stable but highlights dependency on equity financing.45
Neutral
Cash Flow
Operating cash flow has been consistently negative, reflecting operational inefficiencies. While there has been a notable increase in investing cash flow, this is offset by the substantial negative free cash flow, indicating liquidity challenges. The free cash flow to net income ratio is unfavorable, pointing towards cash flow issues.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 176.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 68.00K | -123.00K | -43.00K | -50.00K | -47.00K | -39.00K | EBIT |
| -48.22M | -33.92M | -29.91M | -32.48M | -32.49M | -26.64M | EBITDA |
| -44.20M | -33.80M | -29.86M | -32.43M | -32.44M | -26.61M | Net Income Common Stockholders |
| -44.32M | -29.07M | -29.15M | -33.94M | -32.76M | -26.05M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 82.97M | 82.97M | 12.59M | 36.83M | 45.00M | 57.31M | Total Assets |
| 89.40M | 89.40M | 123.02M | 38.48M | 47.13M | 60.00M | Total Debt |
| 1.34M | 1.34M | 9.18M | 14.63M | 14.21M | 356.00K | Net Debt |
| -31.06M | -31.06M | -3.41M | -22.20M | -30.79M | -56.96M | Total Liabilities |
| 6.86M | 6.86M | 15.56M | 21.40M | 19.85M | 5.46M | Stockholders Equity |
| 82.55M | 82.55M | 107.46M | 17.07M | 27.28M | 54.55M |
| Cash Flow | Free Cash Flow | ||||
| -35.12M | -31.85M | -28.33M | -28.95M | -29.03M | -23.10M | Operating Cash Flow |
| -35.06M | -31.71M | -28.18M | -28.95M | -29.00M | -23.09M | Investing Cash Flow |
| 15.19M | 59.43M | -107.37M | 0.00 | -32.00K | -9.00K | Financing Cash Flow |
| 10.02M | -7.91M | 111.31M | 20.77M | 16.72M | 73.21K |
Trevi Therapeutics Technical Analysis
Positive
6.40
Price Trends
4.70
Positive
4.03
Positive
3.49
Positive
Market Momentum
0.62
Negative
69.96
Neutral
46.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRVI, the sentiment is Positive. The current price of 6.4 is above the 20-day moving average (MA) of 5.65, above the 50-day MA of 4.70, and above the 200-day MA of 3.49, indicating a bullish trend. The MACD of 0.62 indicates Negative momentum. The RSI at 69.96 is Neutral, neither overbought nor oversold. The STOCH value of 46.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TRVI.
Trevi Therapeutics Risk Analysis
Trevi Therapeutics disclosed 72 risk factors in its most recent earnings report. Trevi Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Trevi Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $11.16B | 35.13 | 14.16% | ― | 24.81% | 33.67% | |
55 Neutral | $618.77M | ― | -52.59% | ― | ― | -60.26% | |
51 Neutral | $6.18B | ― | -231.63% | ― | 42.53% | -15.29% | |
49 Neutral | $6.94B | 0.66 | -52.58% | 2.47% | 22.65% | 0.94% | |
48 Neutral | $498.00M | ― | -63.37% | ― | -52.30% | 27.13% | |
45 Neutral | $5.38B | ― | 435.49% | ― | 145.34% | 3.20% | |
43 Neutral | $2.71B | ― | -27.85% | ― | ― | -10.19% |
* Healthcare Sector Average
Performance Comparison
TRVI
Trevi Therapeutics
6.61
3.22
94.99%
CYTK
Cytokinetics
44.55
-26.60
-37.39%
NBIX
Neurocrine
116.18
-24.98
-17.70%
SAGE
SAGE Therapeutics
8.53
-10.09
-54.19%
XENE
Xenon
34.90
-7.76
-18.19%
AXSM
Axsome Therapeutics
120.36
43.64
56.88%
Trevi Therapeutics Earnings Call Summary
Earnings Call Date: Mar 18, 2025 | % Change Since: -2.44% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant clinical successes and a strong financial position, but increased losses and expenses present challenges. Overall, the positive clinical outcomes suggest a promising outlook for the company despite the financial setbacks.Highlights
Positive Data Readouts
Trevi Therapeutics reported three positive data readouts in 2024, including the Human Abuse Potential study, the Sample Size Re-Estimation, and the RIVER study, indicating strong clinical progress for Haduvio.
Successful Human Abuse Potential Study
The Human Abuse Potential study showed statistically significant lower relative drug liking for nalbuphine compared to butorphanol, supporting its continued unscheduled status by the DEA.
RIVER Study Success
The RIVER study in RCC patients achieved a statistically significant reduction in 24-hour objective cough frequency, with a 57% placebo-adjusted change from baseline.
Financial Stability
Trevi completed a $50 million unwritten offering, resulting in cash, cash equivalents, and marketable securities totaling $107.6 million, providing a cash runway into the second half of 2026.
Lowlights
Increased Net Loss
The net loss for Q4 2024 was $11.4 million, up from $7.8 million in Q4 2023, primarily due to increased R&D expenses.
Higher R&D Expenses
R&D expenses increased to $9.3 million in Q4 2024 from $6.5 million in Q4 2023, driven by clinical trial costs and personnel expenses.
Higher G&A Expenses
G&A expenses rose to $2.9 million in Q4 2024 from $2.4 million in the same period in 2023, attributed to increased stock-based compensation and personnel expenses.
Company Guidance
During the Trevi Therapeutics Fourth Quarter and Year End 2024 Earnings Conference Call, the company provided detailed guidance on the progress and future plans for their lead drug, Haduvio. Trevi reported a net loss of $11.4 million for Q4 2024, compared to $7.8 million in the prior year, with R&D expenses rising to $9.3 million. The company successfully completed several clinical trials, including the Human Abuse Potential study, the CORAL study in IPF chronic cough, and the RIVER study in refractory chronic cough, with trials conducted across 11 countries. Trevi's cash reserves stood at $107.6 million, which includes a $50 million offering completed in December. The company’s cash runway extends into the second half of 2026, with expected quarterly cash burn of $12 million to $14 million in the first two quarters of 2025. Upcoming milestones include a Phase 2b readout for the CORAL trial expected in Q2 2025, and plans for an End-of-Phase 2 meeting with the FDA by the end of 2025. The company is also preparing for the next RCC trial while continuing to develop Haduvio for IPF and RCC.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.